Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Pipeline Review, H2 2016’, provides in depth analysis on Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted pipeline therapeutics.

The report provides comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)

The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects

The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Chrysalis Pharma SAS

Griffin Discoveries BV

Johnson & Johnson

OSE Immunotherapeutics

Palau Pharma, S.A.

Sensorion S.A.

Ziarco Pharma Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Overview 7

Therapeutics Development 8

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Stage of Development 8

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Therapy Area 9

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Indication 10

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Companies 13

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development 21

Chrysalis Pharma SAS 21

Griffin Discoveries BV 22

Johnson & Johnson 23

OSE Immunotherapeutics 24

Palau Pharma, S.A. 25

Sensorion S.A. 26

Ziarco Pharma Ltd 27

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles 28

GD-134 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

GD-136 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

GD-48 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

JNJ-28307474 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

JNJ-28610244 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

JNJ-40279486 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

SENS-218 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

toreforant tartrate - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

tritoqualine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

UR-63325 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ZPL-389 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Projects 46

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products 49

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Featured News & Press Releases 50

Sep 19, 2016: Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress 50

Sep 07, 2016: Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK 50

Sep 01, 2016: Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo 51

Jun 13, 2016: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients 52

May 16, 2016: Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 53

May 12, 2016: Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting 53

Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting 54

Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389 55

Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 55

Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis 56

Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo 57

Jun 18, 2014: Ziarco Secures £1.7M Grant from UK’s Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis 58

Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325 58

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Chrysalis Pharma SAS, H2 2016 21

Pipeline by Griffin Discoveries BV, H2 2016 22

Pipeline by Johnson & Johnson, H2 2016 23

Pipeline by OSE Immunotherapeutics, H2 2016 24

Pipeline by Palau Pharma, S.A., H2 2016 25

Pipeline by Sensorion S.A., H2 2016 26

Pipeline by Ziarco Pharma Ltd, H2 2016 27

Dormant Projects, H2 2016 46

Dormant Projects (Contd..1), H2 2016 47

Dormant Projects (Contd..2), H2 2016 48

Discontinued Products, H2 2016 49

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports